Publications

Manufacturing in a Tariff-Driven World: Why Commercial Biologics Capacity Must Align with Market Demand

Contract Pharma, May 2026 Feature Article

Trade policy and tariff dynamics are reshaping global supply chain strategies across the biopharmaceutical industry. For biologics manufacturers, commercial capacity decisions can no longer be based solely on technical capability or available scale — they must align with demand geography, regulatory considerations, and long-term market access strategy.

We’re proud to share that Contract Pharma has featured our latest article:

“Manufacturing in a Tariff-Driven World: Why Commercial Biologics Capacity Must Align with Market Demand”

Authored by
Steve Lam, Chief Executive Officer
Marc Goemans, MSc MBA, Chief Commercial Officer
John Mosack, General Manager & VP – San Diego

In the piece, we explore:

• How tariff pressures are influencing biologics supply chain strategy
• Why commercial-scale capacity must reflect end-market demand
• The growing role of geographic alignment in commercialization planning
• How regulatory and trade environments are shaping manufacturing decisions

As global trade dynamics continue to evolve, sponsors are asking a different question:

Not just “Where can we manufacture?”
But “Where should we manufacture to support long-term commercial success?”

View PDF

View on Contract Pharma

Operational and Validated: 2000L Single-Use Commercial Capacity in the U.S.
Bora Biologics’ expanded 2000L single-use capabilities support late-stage development and commercial GMP manufacturing in our San Diego FDA registered facility.

Filter

Bora Biologics

the logical choice

Join the ranks of biopharma pioneers who trust us.
Explore how we minimize risks and accelerate your success.

Partner with us

Client-Centric

100% commitment to supporting your success

We have been the client, bringing multiple biologics from IND to BLA. Your needs and goals are at the forefront of our approach. By involving you in every step of the process, we ensure transparency and alignment, reducing the likelihood of misunderstandings and ensuring the outcome meets your expectations.

Experience

14 years developing & manufacturing biologics

We have honed our ability to navigate complexities. Our track record from concept to commercialization means we can apply best practices and lessons learned, ensuring smoother project execution.

Expertise

125 seasoned scientists & regulatory professionals

Our team exudes deep knowledge and specialized skills. This expertise allows us to foresee potential challenges and implement proactive solutions, reducing the likelihood of setbacks.

Commercial-Ready

US FDA registered GMP manufacturing facility

We focus on delivering solutions that are ready for market. With clinical to commercial scale facilities consistently meeting compliance standards, we ensure your project is primed for success, minimizing the risk of costly revisions or delays.

Allied

access to global CDMO resources

Our partnership with Bora Pharmaceuticals provides additional resources and insights. This network enables us to leverage shared knowledge and expertise, further mitigating risks and accelerating the overall success of your project.